Loading…
Urinary metabolites of histamine and leukotrienes before and after placebo‐controlled challenge with ASA and food additives in chronic urticaria patients
Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU). Methods: Twen...
Saved in:
Published in: | Allergy (Copenhagen) 2002-12, Vol.57 (12), p.1180-1186 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4287-3ea3a108aa58ad3321e0148fb03e32ee59824bc84f149590d2dcee0e25efe7c43 |
---|---|
cites | cdi_FETCH-LOGICAL-c4287-3ea3a108aa58ad3321e0148fb03e32ee59824bc84f149590d2dcee0e25efe7c43 |
container_end_page | 1186 |
container_issue | 12 |
container_start_page | 1180 |
container_title | Allergy (Copenhagen) |
container_volume | 57 |
creator | Di Lorenzo, G. Pacor, M. L. Vignola, A. M. Profita, M. Esposito‐Pellitteri, M. Biasi, D. Corrocher, R. Caruso, C. |
description | Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU).
Methods: Twenty patients with CU were studied. They were selected on the basis of double‐blind placebo‐controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (five patients). We recruited 15 healthy volunteers as controls (group A). During a second challenge, groups B and C were challenged double‐blind with a single dose of ASA, or a specific food additive, or placebo. The healthy group was challenged only with a placebo (talc capsule). Patients in groups B and C were challenged twice: with placebo (as groups B1 and C1) and with ASA (groups B2 and C2) or food additives (C2). Four samples of urine were collected; one during the night before the specific or sham challenge (baseline), and three at 2, 6 and 24 h after the challenge. Urinary methylhistamine (N‐MH) and LTE4 were analyzed and normalized for urinary creatinine.
Results: For urinary N‐MH at baseline, there was a significant difference only between group A and groups B1, B2, C1 and C2 (A vs. B1, P |
doi_str_mv | 10.1034/j.1398-9995.2002.23767.x |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18706753</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18706753</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4287-3ea3a108aa58ad3321e0148fb03e32ee59824bc84f149590d2dcee0e25efe7c43</originalsourceid><addsrcrecordid>eNqNkc9u1DAQxiMEokvhFZAvcEvwv2ycE1pVUJBW6gF6thxnzHpx7MV2aHvjEXrn7XgSnO6KXjmN5fl9M6PvqypEcEMw4-_2DWG9qPu-bxuKMW0o69Zdc_ukWv1rPK1WmOC25i0TZ9WLlPYY4472-Hl1Rihfc8y7VfX7Olqv4h2aIKshOJshoWDQzqasJusBKT8iB_P3kKMFX7oDmBCP_8pkiOjglIYh_Pl1r4PPMTgHI9I7Var_BujG5h3afNk8KEwIRTaONtufZZb1BYzBW43mmK1W0Sp0ULlsyull9cwol-DVqZ5X1x8_fL34VG-vLj9fbLa15lR0NQPFFMFCqVaokTFKABMuzIAZMArQ9oLyQQtuCO_bHo901AAYaAsGOs3ZefX2OPcQw48ZUpaTTRqcUx7CnCQRHV53LSugOII6hpQiGHmIdiruSYLlEozcy8V_ufgvl2DkQzDytkhfn3bMwwTjo_CURAHenACVtHImKq9teuQ4Z7gVC_f-yN1YB3f_fYDcbLf0anmzv7SYrqU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18706753</pqid></control><display><type>article</type><title>Urinary metabolites of histamine and leukotrienes before and after placebo‐controlled challenge with ASA and food additives in chronic urticaria patients</title><source>Wiley</source><source>Alma/SFX Local Collection</source><creator>Di Lorenzo, G. ; Pacor, M. L. ; Vignola, A. M. ; Profita, M. ; Esposito‐Pellitteri, M. ; Biasi, D. ; Corrocher, R. ; Caruso, C.</creator><creatorcontrib>Di Lorenzo, G. ; Pacor, M. L. ; Vignola, A. M. ; Profita, M. ; Esposito‐Pellitteri, M. ; Biasi, D. ; Corrocher, R. ; Caruso, C.</creatorcontrib><description><![CDATA[Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU).
Methods: Twenty patients with CU were studied. They were selected on the basis of double‐blind placebo‐controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (five patients). We recruited 15 healthy volunteers as controls (group A). During a second challenge, groups B and C were challenged double‐blind with a single dose of ASA, or a specific food additive, or placebo. The healthy group was challenged only with a placebo (talc capsule). Patients in groups B and C were challenged twice: with placebo (as groups B1 and C1) and with ASA (groups B2 and C2) or food additives (C2). Four samples of urine were collected; one during the night before the specific or sham challenge (baseline), and three at 2, 6 and 24 h after the challenge. Urinary methylhistamine (N‐MH) and LTE4 were analyzed and normalized for urinary creatinine.
Results: For urinary N‐MH at baseline, there was a significant difference only between group A and groups B1, B2, C1 and C2 (A vs. B1, P < 0.0001; A vs. B2, P < 0.0001; A vs. C1, P < 0.0001; A vs. C2, P < 0.0001). We detected a significant variation in urinary methylhistamine excretion only in group C2 after 2 h, 6 h and 24 h (P < 0.0001). However, no variations were observed in N‐MH excretion rate in the other groups (A, B1, C1) after challenge with placebo, and in B2 after challenge with ASA 20 mg. For urinary LTE4 at baseline no differences were found between the mean values for the different groups. After specific challenge, only C2 patients showed significantly increased excretion rates of urinary LTE4 compared with the other groups challenged with placebo (A, B1, C1), or ASA (B2) (P < 0.0001). No significant correlation was seen between urinary LTE4 and methylhistamine excretion rate in any patients.
Conclusion: Our results show that urinary excretion of N‐MH and LTE4 is different for CU patients without ASA or food hypersensitivity, compared to those with CU with ASA or food additive hypersensitivity after specific challenge.]]></description><identifier>ISSN: 0105-4538</identifier><identifier>EISSN: 1398-9995</identifier><identifier>DOI: 10.1034/j.1398-9995.2002.23767.x</identifier><identifier>PMID: 12464047</identifier><identifier>CODEN: LLRGDY</identifier><language>eng</language><publisher>Oxford, UK: Munksgaard International Publishers</publisher><subject><![CDATA[Administration, Oral ; Adult ; Allergic diseases ; ASA ; Aspirin - administration & dosage ; Aspirin - adverse effects ; Biological and medical sciences ; Biomarkers - urine ; Bronchoconstrictor Agents - administration & dosage ; Bronchoconstrictor Agents - adverse effects ; Chronic Disease ; chronic urticaria ; Controlled Clinical Trials as Topic ; Cyclooxygenase Inhibitors - administration & dosage ; Cyclooxygenase Inhibitors - adverse effects ; Dose-Response Relationship, Drug ; Double-Blind Method ; double‐blind placebo‐controlled ; Drug Hypersensitivity - etiology ; Drug Hypersensitivity - urine ; Female ; food additive ; Food Additives - administration & dosage ; Food Additives - adverse effects ; Humans ; Immunopathology ; Italy ; Leukotriene E4 - urine ; Male ; Medical sciences ; Methylhistamines - urine ; Middle Aged ; Skin allergic diseases. Stinging insect allergies ; Sodium Benzoate - administration & dosage ; Sodium Benzoate - adverse effects ; Sodium Glutamate - administration & dosage ; Sodium Glutamate - adverse effects ; Sulfites - administration & dosage ; Sulfites - adverse effects ; Tartrazine - administration & dosage ; Tartrazine - adverse effects ; Time Factors ; urinary LTE4 ; urinary methylhistamine ; Urticaria - urine]]></subject><ispartof>Allergy (Copenhagen), 2002-12, Vol.57 (12), p.1180-1186</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4287-3ea3a108aa58ad3321e0148fb03e32ee59824bc84f149590d2dcee0e25efe7c43</citedby><cites>FETCH-LOGICAL-c4287-3ea3a108aa58ad3321e0148fb03e32ee59824bc84f149590d2dcee0e25efe7c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14430587$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12464047$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Lorenzo, G.</creatorcontrib><creatorcontrib>Pacor, M. L.</creatorcontrib><creatorcontrib>Vignola, A. M.</creatorcontrib><creatorcontrib>Profita, M.</creatorcontrib><creatorcontrib>Esposito‐Pellitteri, M.</creatorcontrib><creatorcontrib>Biasi, D.</creatorcontrib><creatorcontrib>Corrocher, R.</creatorcontrib><creatorcontrib>Caruso, C.</creatorcontrib><title>Urinary metabolites of histamine and leukotrienes before and after placebo‐controlled challenge with ASA and food additives in chronic urticaria patients</title><title>Allergy (Copenhagen)</title><addtitle>Allergy</addtitle><description><![CDATA[Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU).
Methods: Twenty patients with CU were studied. They were selected on the basis of double‐blind placebo‐controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (five patients). We recruited 15 healthy volunteers as controls (group A). During a second challenge, groups B and C were challenged double‐blind with a single dose of ASA, or a specific food additive, or placebo. The healthy group was challenged only with a placebo (talc capsule). Patients in groups B and C were challenged twice: with placebo (as groups B1 and C1) and with ASA (groups B2 and C2) or food additives (C2). Four samples of urine were collected; one during the night before the specific or sham challenge (baseline), and three at 2, 6 and 24 h after the challenge. Urinary methylhistamine (N‐MH) and LTE4 were analyzed and normalized for urinary creatinine.
Results: For urinary N‐MH at baseline, there was a significant difference only between group A and groups B1, B2, C1 and C2 (A vs. B1, P < 0.0001; A vs. B2, P < 0.0001; A vs. C1, P < 0.0001; A vs. C2, P < 0.0001). We detected a significant variation in urinary methylhistamine excretion only in group C2 after 2 h, 6 h and 24 h (P < 0.0001). However, no variations were observed in N‐MH excretion rate in the other groups (A, B1, C1) after challenge with placebo, and in B2 after challenge with ASA 20 mg. For urinary LTE4 at baseline no differences were found between the mean values for the different groups. After specific challenge, only C2 patients showed significantly increased excretion rates of urinary LTE4 compared with the other groups challenged with placebo (A, B1, C1), or ASA (B2) (P < 0.0001). No significant correlation was seen between urinary LTE4 and methylhistamine excretion rate in any patients.
Conclusion: Our results show that urinary excretion of N‐MH and LTE4 is different for CU patients without ASA or food hypersensitivity, compared to those with CU with ASA or food additive hypersensitivity after specific challenge.]]></description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Allergic diseases</subject><subject>ASA</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - urine</subject><subject>Bronchoconstrictor Agents - administration & dosage</subject><subject>Bronchoconstrictor Agents - adverse effects</subject><subject>Chronic Disease</subject><subject>chronic urticaria</subject><subject>Controlled Clinical Trials as Topic</subject><subject>Cyclooxygenase Inhibitors - administration & dosage</subject><subject>Cyclooxygenase Inhibitors - adverse effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>double‐blind placebo‐controlled</subject><subject>Drug Hypersensitivity - etiology</subject><subject>Drug Hypersensitivity - urine</subject><subject>Female</subject><subject>food additive</subject><subject>Food Additives - administration & dosage</subject><subject>Food Additives - adverse effects</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Italy</subject><subject>Leukotriene E4 - urine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylhistamines - urine</subject><subject>Middle Aged</subject><subject>Skin allergic diseases. Stinging insect allergies</subject><subject>Sodium Benzoate - administration & dosage</subject><subject>Sodium Benzoate - adverse effects</subject><subject>Sodium Glutamate - administration & dosage</subject><subject>Sodium Glutamate - adverse effects</subject><subject>Sulfites - administration & dosage</subject><subject>Sulfites - adverse effects</subject><subject>Tartrazine - administration & dosage</subject><subject>Tartrazine - adverse effects</subject><subject>Time Factors</subject><subject>urinary LTE4</subject><subject>urinary methylhistamine</subject><subject>Urticaria - urine</subject><issn>0105-4538</issn><issn>1398-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqNkc9u1DAQxiMEokvhFZAvcEvwv2ycE1pVUJBW6gF6thxnzHpx7MV2aHvjEXrn7XgSnO6KXjmN5fl9M6PvqypEcEMw4-_2DWG9qPu-bxuKMW0o69Zdc_ukWv1rPK1WmOC25i0TZ9WLlPYY4472-Hl1Rihfc8y7VfX7Olqv4h2aIKshOJshoWDQzqasJusBKT8iB_P3kKMFX7oDmBCP_8pkiOjglIYh_Pl1r4PPMTgHI9I7Var_BujG5h3afNk8KEwIRTaONtufZZb1BYzBW43mmK1W0Sp0ULlsyull9cwol-DVqZ5X1x8_fL34VG-vLj9fbLa15lR0NQPFFMFCqVaokTFKABMuzIAZMArQ9oLyQQtuCO_bHo901AAYaAsGOs3ZefX2OPcQw48ZUpaTTRqcUx7CnCQRHV53LSugOII6hpQiGHmIdiruSYLlEozcy8V_ufgvl2DkQzDytkhfn3bMwwTjo_CURAHenACVtHImKq9teuQ4Z7gVC_f-yN1YB3f_fYDcbLf0anmzv7SYrqU</recordid><startdate>200212</startdate><enddate>200212</enddate><creator>Di Lorenzo, G.</creator><creator>Pacor, M. L.</creator><creator>Vignola, A. M.</creator><creator>Profita, M.</creator><creator>Esposito‐Pellitteri, M.</creator><creator>Biasi, D.</creator><creator>Corrocher, R.</creator><creator>Caruso, C.</creator><general>Munksgaard International Publishers</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>200212</creationdate><title>Urinary metabolites of histamine and leukotrienes before and after placebo‐controlled challenge with ASA and food additives in chronic urticaria patients</title><author>Di Lorenzo, G. ; Pacor, M. L. ; Vignola, A. M. ; Profita, M. ; Esposito‐Pellitteri, M. ; Biasi, D. ; Corrocher, R. ; Caruso, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4287-3ea3a108aa58ad3321e0148fb03e32ee59824bc84f149590d2dcee0e25efe7c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Allergic diseases</topic><topic>ASA</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - urine</topic><topic>Bronchoconstrictor Agents - administration & dosage</topic><topic>Bronchoconstrictor Agents - adverse effects</topic><topic>Chronic Disease</topic><topic>chronic urticaria</topic><topic>Controlled Clinical Trials as Topic</topic><topic>Cyclooxygenase Inhibitors - administration & dosage</topic><topic>Cyclooxygenase Inhibitors - adverse effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>double‐blind placebo‐controlled</topic><topic>Drug Hypersensitivity - etiology</topic><topic>Drug Hypersensitivity - urine</topic><topic>Female</topic><topic>food additive</topic><topic>Food Additives - administration & dosage</topic><topic>Food Additives - adverse effects</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Italy</topic><topic>Leukotriene E4 - urine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylhistamines - urine</topic><topic>Middle Aged</topic><topic>Skin allergic diseases. Stinging insect allergies</topic><topic>Sodium Benzoate - administration & dosage</topic><topic>Sodium Benzoate - adverse effects</topic><topic>Sodium Glutamate - administration & dosage</topic><topic>Sodium Glutamate - adverse effects</topic><topic>Sulfites - administration & dosage</topic><topic>Sulfites - adverse effects</topic><topic>Tartrazine - administration & dosage</topic><topic>Tartrazine - adverse effects</topic><topic>Time Factors</topic><topic>urinary LTE4</topic><topic>urinary methylhistamine</topic><topic>Urticaria - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Lorenzo, G.</creatorcontrib><creatorcontrib>Pacor, M. L.</creatorcontrib><creatorcontrib>Vignola, A. M.</creatorcontrib><creatorcontrib>Profita, M.</creatorcontrib><creatorcontrib>Esposito‐Pellitteri, M.</creatorcontrib><creatorcontrib>Biasi, D.</creatorcontrib><creatorcontrib>Corrocher, R.</creatorcontrib><creatorcontrib>Caruso, C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Allergy (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Lorenzo, G.</au><au>Pacor, M. L.</au><au>Vignola, A. M.</au><au>Profita, M.</au><au>Esposito‐Pellitteri, M.</au><au>Biasi, D.</au><au>Corrocher, R.</au><au>Caruso, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary metabolites of histamine and leukotrienes before and after placebo‐controlled challenge with ASA and food additives in chronic urticaria patients</atitle><jtitle>Allergy (Copenhagen)</jtitle><addtitle>Allergy</addtitle><date>2002-12</date><risdate>2002</risdate><volume>57</volume><issue>12</issue><spage>1180</spage><epage>1186</epage><pages>1180-1186</pages><issn>0105-4538</issn><eissn>1398-9995</eissn><coden>LLRGDY</coden><abstract><![CDATA[Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU).
Methods: Twenty patients with CU were studied. They were selected on the basis of double‐blind placebo‐controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (five patients). We recruited 15 healthy volunteers as controls (group A). During a second challenge, groups B and C were challenged double‐blind with a single dose of ASA, or a specific food additive, or placebo. The healthy group was challenged only with a placebo (talc capsule). Patients in groups B and C were challenged twice: with placebo (as groups B1 and C1) and with ASA (groups B2 and C2) or food additives (C2). Four samples of urine were collected; one during the night before the specific or sham challenge (baseline), and three at 2, 6 and 24 h after the challenge. Urinary methylhistamine (N‐MH) and LTE4 were analyzed and normalized for urinary creatinine.
Results: For urinary N‐MH at baseline, there was a significant difference only between group A and groups B1, B2, C1 and C2 (A vs. B1, P < 0.0001; A vs. B2, P < 0.0001; A vs. C1, P < 0.0001; A vs. C2, P < 0.0001). We detected a significant variation in urinary methylhistamine excretion only in group C2 after 2 h, 6 h and 24 h (P < 0.0001). However, no variations were observed in N‐MH excretion rate in the other groups (A, B1, C1) after challenge with placebo, and in B2 after challenge with ASA 20 mg. For urinary LTE4 at baseline no differences were found between the mean values for the different groups. After specific challenge, only C2 patients showed significantly increased excretion rates of urinary LTE4 compared with the other groups challenged with placebo (A, B1, C1), or ASA (B2) (P < 0.0001). No significant correlation was seen between urinary LTE4 and methylhistamine excretion rate in any patients.
Conclusion: Our results show that urinary excretion of N‐MH and LTE4 is different for CU patients without ASA or food hypersensitivity, compared to those with CU with ASA or food additive hypersensitivity after specific challenge.]]></abstract><cop>Oxford, UK</cop><pub>Munksgaard International Publishers</pub><pmid>12464047</pmid><doi>10.1034/j.1398-9995.2002.23767.x</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0105-4538 |
ispartof | Allergy (Copenhagen), 2002-12, Vol.57 (12), p.1180-1186 |
issn | 0105-4538 1398-9995 |
language | eng |
recordid | cdi_proquest_miscellaneous_18706753 |
source | Wiley; Alma/SFX Local Collection |
subjects | Administration, Oral Adult Allergic diseases ASA Aspirin - administration & dosage Aspirin - adverse effects Biological and medical sciences Biomarkers - urine Bronchoconstrictor Agents - administration & dosage Bronchoconstrictor Agents - adverse effects Chronic Disease chronic urticaria Controlled Clinical Trials as Topic Cyclooxygenase Inhibitors - administration & dosage Cyclooxygenase Inhibitors - adverse effects Dose-Response Relationship, Drug Double-Blind Method double‐blind placebo‐controlled Drug Hypersensitivity - etiology Drug Hypersensitivity - urine Female food additive Food Additives - administration & dosage Food Additives - adverse effects Humans Immunopathology Italy Leukotriene E4 - urine Male Medical sciences Methylhistamines - urine Middle Aged Skin allergic diseases. Stinging insect allergies Sodium Benzoate - administration & dosage Sodium Benzoate - adverse effects Sodium Glutamate - administration & dosage Sodium Glutamate - adverse effects Sulfites - administration & dosage Sulfites - adverse effects Tartrazine - administration & dosage Tartrazine - adverse effects Time Factors urinary LTE4 urinary methylhistamine Urticaria - urine |
title | Urinary metabolites of histamine and leukotrienes before and after placebo‐controlled challenge with ASA and food additives in chronic urticaria patients |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A43%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20metabolites%20of%20histamine%20and%20leukotrienes%20before%20and%20after%20placebo%E2%80%90controlled%20challenge%20with%20ASA%20and%20food%20additives%20in%20chronic%20urticaria%20patients&rft.jtitle=Allergy%20(Copenhagen)&rft.au=Di%20Lorenzo,%20G.&rft.date=2002-12&rft.volume=57&rft.issue=12&rft.spage=1180&rft.epage=1186&rft.pages=1180-1186&rft.issn=0105-4538&rft.eissn=1398-9995&rft.coden=LLRGDY&rft_id=info:doi/10.1034/j.1398-9995.2002.23767.x&rft_dat=%3Cproquest_cross%3E18706753%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4287-3ea3a108aa58ad3321e0148fb03e32ee59824bc84f149590d2dcee0e25efe7c43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=18706753&rft_id=info:pmid/12464047&rfr_iscdi=true |